Tuesday, May 11, 2021 10:49:38 PM
I’m sold. What’s a good PT to get into tmw I was thinking setting it for 26.50 see if I can start there and average as I go.
How soon are the results?
How soon are the results?
Recent ANVS News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:39:11 PM
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Annovis Publishes Historical Review of Buntanetap in The Scientist • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:19:03 PM
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 09:06:04 PM
- Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results • GlobeNewswire Inc. • 03/16/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 09:15:44 PM
- Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 02:00:47 PM
- Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 09:28:34 PM
- Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients • GlobeNewswire Inc. • 12/18/2025 09:35:00 PM
- Annovis to Host Corporate Update Webinar on January 28, 2026 • GlobeNewswire Inc. • 12/16/2025 01:00:00 PM
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group • GlobeNewswire Inc. • 12/03/2025 01:00:00 PM
- Annovis Announces Two Presentations at the CTAD 2025 Conference • GlobeNewswire Inc. • 11/24/2025 01:00:00 PM
- Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study • GlobeNewswire Inc. • 11/18/2025 01:00:00 PM
- Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients • GlobeNewswire Inc. • 11/17/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2025 02:17:18 PM
- Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/12/2025 01:00:00 PM
- Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program • GlobeNewswire Inc. • 11/06/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 09:07:47 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/28/2025 06:51:58 PM
